Adherex ends R&D collaboration with Shire

Ottawa’s Adherex Technologies Inc has ended its co-development arrangement with Shire Pharmaceuticals by mutual agreement. The biotechnology firm specializing in cell adhesion technologies is now in discussions with another major pharamceutical partner to develop its Exherin cancer compound, with the stipulation that such a collaboration that does not require matching R&D spending. Adherex notes that Shire was originally chosen as a partner out of a field of 26 firms that expressed interest in its technology....